<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40887510</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-2267</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of cancer survivorship : research and practice</Title><ISOAbbreviation>J Cancer Surviv</ISOAbbreviation></Journal><ArticleTitle>Managing, not lessening, uncertainty: a novel mind-body intervention for fear of cancer recurrence.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11764-025-01886-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">After a cancer diagnosis, uncertainty is common. IN FOCUS is a pilot randomized controlled trial that evaluated the feasibility and acceptability of a virtual mind-body group resiliency intervention on fear of cancer recurrence (FCR). The current study examines secondary outcomes of this trial, specifically exploring changes in related mental health constructs, which will contribute to our understanding of symptom relief as well as diagnostic overlap and discrepancies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A single-blinded, 2-arm, randomized controlled trial was conducted from July 2021 to March 2022 comparing IN FOCUS (8 weekly, 90-min, synchronous virtual group classes teaching cognitive behavioral techniques, relaxation training, meditation, adaptive health behaviors, and positive psychology skills) to usual care (synchronous virtual community group support referral) among cancer survivors with non-metastatic disease and clinically elevated FCR (FCR Inventory severity&#x2009;&#x2265;&#x2009;16). Secondary outcomes assessed included anxiety (PHQ-4), depression (PHQ-4), worry (Penn State Worry Questionnaire), health anxiety (Short Health Anxiety Inventory), intolerance of uncertainty (Intolerance of Uncertainty Scale), and cancer-related uncertainty (Mishel Uncertainty in Illness Scale-Survivor version). Intent-to-treat analyses with separate general linear mixed models were used to identify group-by-time effects (Cohen's d; 0.5 a medium effect, 0.8 a large effect) from baseline through 2&#xa0;months and 5&#xa0;months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-four survivors enrolled (25-73&#xa0;years old, M&#x2009;=&#x2009;7&#xa0;years since diagnosis, 83% female). By 5&#xa0;months, IN FOCUS produced large effect size reductions in anxiety (d&#x2009;= -&#x2009;0.83), medium effect size reductions in depression (d&#x2009;= -&#x2009;0.45), health anxiety (d&#x2009;= -&#x2009;0.54), and prospective intolerance of uncertainty (d&#x2009;= -&#x2009;0.54), and small effect size reductions in inhibitory intolerance of uncertainty (d&#x2009;= -&#x2009;0.39) and worry (d&#x2009;= -&#x2009;0.38). Notably, cancer-related uncertainty did not change in either study arm (d&#x2009;= -&#x2009;0.14).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although in the parent trial IN FOCUS did not have a sustained effect on FCR, secondary analyses showed that IN FOCUS produced improvements in anxiety, depression, worry, and health anxiety 3&#xa0;months post-treatment.</AbstractText><AbstractText Label="GOV ID" NlmCategory="UNASSIGNED">NCT04876599, Mind-body Resiliency Intervention for Fear of Cancer Recurrence.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">https://clinicaltrials.gov/study/NCT04876599 IMPLICATIONS FOR CANCER SURVIVORS: While cancer survivors' uncertainties remained steady over time, their capacity to tolerate uncertainty seemed to improve after engaging in a novel virtual mind-body intervention.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Christie</LastName><ForeName>Aimee J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>The University of Texas at MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolden</LastName><ForeName>Caleb</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Elyse R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Gloria Y</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Cleirigh</LastName><ForeName>Conall</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peppercorn</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denninger</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschberg</LastName><ForeName>April M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markwart</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siefring</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizrach</LastName><ForeName>Helen R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Andrea J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, 100 Cambridge St., 16Th Floor, Boston, MA, 02114, USA. hall@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. hall@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04876599</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>T32AT000051, K23AT010157, K24AT009465</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24CA197382</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32AT000051, K23AT010157, K24AT009465</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24CA197382</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cancer Surviv</MedlineTA><NlmUniqueID>101307557</NlmUniqueID><ISSNLinking>1932-2259</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">Fear of cancer recurrence</Keyword><Keyword MajorTopicYN="N">Intervention</Keyword><Keyword MajorTopicYN="N">Mind&#x2013;body</Keyword><Keyword MajorTopicYN="N">Psycho-oncology</Keyword><Keyword MajorTopicYN="N">Uncertainty</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This clinical trial had IRB approval (Dana-Farber/Harvard Cancer Center; Protocol 21&#x2013;090). All procedures were monitored by the Dana-Farber Harvard Cancer Center Institutional Review Board (Protocol ID: 21&#x2013;090) and an independent monitoring committee. All procedures conformed to the Declaration of Helsinki ethical standards. All participants provided electronic informed consent. Competing interests: DLH has received consultation fees from Goodpath, Inc. All other authors have no competing interests to declare. Permission to reproduce material from other sources: Not applicable. All content is original.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40887510</ArticleId><ArticleId IdType="doi">10.1007/s11764-025-01886-2</ArticleId><ArticleId IdType="pii">10.1007/s11764-025-01886-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Luigjes-Huizer YL, Tauber NM, Humphris G, Kasparian NA, Lam WWT, Lebel S, et al. What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psycho-Oncol. 2022;31(6):879&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.5921</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7(3):300&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-013-0272-z</ArticleId><ArticleId IdType="pubmed">23475398</ArticleId></ArticleIdList></Reference><Reference><Citation>Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psycho-Oncol. 2013;22(5):978&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.3114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebel S, Ozakinci G, Humphris G, Thewes B, Prins J, Dinkel A, et al. Current state and future prospects of research on fear of cancer recurrence. Psychooncology. 2017;26(4):424&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4103</ArticleId><ArticleId IdType="pubmed">26891602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vachon E, Krueger E, Champion VL, Haggstrom DA, Cella D, Cohee AA. The impact of fear of cancer recurrence on healthcare utilization among long-term breast cancer survivors recruited through ECOG-ACRIN trials. Psychooncology. 2021;30(3):279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.5568</ArticleId><ArticleId IdType="pubmed">33022832</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JTW, Pearce A, Smith AB. A systematic review of fear of cancer recurrence related healthcare use and intervention cost-effectiveness. Psycho-Oncol. 2021;30(8):1185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.5673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Jimenez RB, Perez GK, Rabin J, Quain K, Yeh GY, et al. Fear of cancer recurrence: a model examination of physical symptoms, emotional distress, and health behavior change. J Oncol Pract. 2019;15(9):e787&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JOP.18.00787</ArticleId><ArticleId IdType="pubmed">31298966</ArticleId><ArticleId IdType="pmc">6743221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Lennes IT, Pirl WF, Friedman ER, Park ER. Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors. Support Care Cancer. 2017;25(5):1401&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27966025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Luberto CM, Philpotts LL, Song R, Park ER, Yeh GY. Mind-body interventions for fear of cancer recurrence: a systematic review and meta-analysis. Psychooncology. 2018;27(11):2546&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4757</ArticleId><ArticleId IdType="pubmed">29744965</ArticleId><ArticleId IdType="pmc">6488231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauber NM, O&#x2019;Toole MS, Dinkel A, Galica J, Humphris G, Lebel S, et al. Effect of psychological intervention on fear of cancer recurrence: a systematic review and meta-analysis. J Clin Oncol. 2019;37(31):2899&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.00572</ArticleId><ArticleId IdType="pubmed">31532725</ArticleId><ArticleId IdType="pmc">6823887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Yeh GY, O&#x2019;Cleirigh C, Wagner LI, Peppercorn J, Denninger J, et al. Pilot randomized controlled trial of in focus: a mind-body resiliency intervention for fear of cancer recurrence. Psychooncology. 2024;33(11):e70026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.70026</ArticleId><ArticleId IdType="pubmed">39549022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Yeh GY, O&#x2019;Cleirigh C, Peppercorn J, Wagner LI, Denninger J, et al. A multi-step approach to adapting a mind-body resiliency intervention for fear of cancer recurrence and uncertainty in survivorship (in focus). Glob Adv Health Med. 2022;11:21649561221074690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21649561221074690</ArticleId><ArticleId IdType="pubmed">35237466</ArticleId><ArticleId IdType="pmc">8883302</ArticleId></ArticleIdList></Reference><Reference><Citation>Park ER, Luberto CM, Chad-Friedman E, Traeger L, Hall DL, Perez GK, et al. A comprehensive resiliency framework: theoretical model, treatment, and evaluation. Glob Adv Health Med. 2021;10:21649561211000304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21649561211000306</ArticleId><ArticleId IdType="pubmed">34377598</ArticleId><ArticleId IdType="pmc">8327002</ArticleId></ArticleIdList></Reference><Reference><Citation>Park ER, Traeger L, Vranceanu AM, Scult M, Lerner JA, Benson H, et al. The development of a patient-centered program based on the relaxation response: the relaxation response resiliency program (3rp). Psychosomatics. 2013;54(2):165&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psym.2012.09.001</ArticleId><ArticleId IdType="pubmed">23352048</ArticleId></ArticleIdList></Reference><Reference><Citation>Park ER, Peppercorn J, El-Jawahri A. Shades of survivorship. J Natl Compr Canc Netw. 2018;16(10):1163&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2018.7071</ArticleId><ArticleId IdType="pubmed">30323085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW, L&#xf6;we B. An ultra-brief screening scale for anxiety and depression: the PHQ&#x2013;4. Psychosomatics. 2009;50(6):613&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19996233</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;we B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the patient health questionnaire-4 (phq-4) in the general population. J Affect Disord. 2010;122(1&#x2013;2):86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2009.06.019</ArticleId><ArticleId IdType="pubmed">19616305</ArticleId></ArticleIdList></Reference><Reference><Citation>Salkovskis PM, Rimes KA, Warwick HM, Clark DM. The health anxiety inventory: development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychol Med. 2002;32(5):843&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291702005822</ArticleId><ArticleId IdType="pubmed">12171378</ArticleId></ArticleIdList></Reference><Reference><Citation>Carleton RN, Norton MPJ, Asmundson GJ. Fearing the unknown: a short version of the intolerance of uncertainty scale. J Anxiety Disord. 2007;21(1):105&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.janxdis.2006.03.014</ArticleId><ArticleId IdType="pubmed">16647833</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State worry questionnaire. Behav Res Ther. 1990;28(6):487&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-7967(90)90135-6</ArticleId><ArticleId IdType="pubmed">2076086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Mishel MH, Germino BB. Living with cancer-related uncertainty: associations with fatigue, insomnia, and affect in younger breast cancer survivors. Support Care Cancer. 2014;22(9):2489&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728586</ArticleId><ArticleId IdType="pmc">6375671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishel MH. The measurement of uncertainty in illness. Nurs Res. 1981;30(5):258&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006199-198109000-00002</ArticleId><ArticleId IdType="pubmed">6912987</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414902</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-015-0424-4</ArticleId><ArticleId IdType="pubmed">25603948</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardell JE, Thewes B, Turner J, Gilchrist J, Sharpe L, Smith A, et al. Fear of cancer recurrence: a theoretical review and novel cognitive processing formulation. J Cancer Surviv. 2016;10(4):663&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-015-0512-5</ArticleId><ArticleId IdType="pubmed">26782171</ArticleId></ArticleIdList></Reference><Reference><Citation>Podina IR, Todea D, Fodor LA. Fear of cancer recurrence and mental health: a comprehensive meta-analysis. Psychooncology. 2023;32(10):1503&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.6205</ArticleId><ArticleId IdType="pubmed">37596855</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom M, Guicherit OR, Hoogwegt MT. Perfectionism, intolerance of uncertainty and coping in relation to fear of cancer recurrence in breast cancer patients. Psycho-Oncol. 2023;32(4):581&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.6102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebel S, Maheu C, Tomei C, Bernstein LJ, Courbasson C, Ferguson S, et al. Towards the validation of a new, blended theoretical model of fear of cancer recurrence. Psychooncology. 2018;27(11):2594&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4880</ArticleId><ArticleId IdType="pubmed">30180279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Sun D, Sun J. Social support and fear of cancer recurrence among Chinese breast cancer survivors: the mediation role of illness uncertainty. Front Psychol. 2022;13: 864129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2022.864129</ArticleId><ArticleId IdType="pubmed">35369168</ArticleId><ArticleId IdType="pmc">8966644</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheu C, Lebel S, Bernstein LJ, Courbasson C, Singh M, Ferguson SE, et al. Fear of cancer recurrence therapy (FORT): a randomized controlled trial. Health Psychol. 2023;42(3):182&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/hea0001253</ArticleId><ArticleId IdType="pubmed">36862474</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuther ET, Davis TE 3rd, Rudy BM, Jenkins WS, Whiting SE, May AC. Intolerance of uncertainty as a mediator of the relationship between perfectionism and obsessive-compulsive symptom severity. Depress Anxiety. 2013;30(8):773&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/da.22100</ArticleId><ArticleId IdType="pubmed">23609998</ArticleId></ArticleIdList></Reference><Reference><Citation>Boswell JF, Thompson-Hollands J, Farchione TJ, Barlow DH. Intolerance of uncertainty: a common factor in the treatment of emotional disorders. J Clin Psychol. 2013;69(6):630&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jclp.21965</ArticleId><ArticleId IdType="pubmed">23381685</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan T, Qan&#x2019;ir Y, Song L. Systematic review of illness uncertainty management interventions for cancer patients and their family caregivers. Support Care Cancer. 2021;29(8):4623&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">33495851</ArticleId><ArticleId IdType="pmc">8236440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishel MH. Uncertainty in illness. Image J Nurs Sch. 1988;20(4):225&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1547-5069.1988.tb00082.x</ArticleId><ArticleId IdType="pubmed">3203947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson G, Madsen LT, Dains JE. Interventions to manage uncertainty and fear of recurrence in female breast cancer survivors: a review of the literature. Clin J Oncol Nurs. 2016;20(6):E155&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1188/16.CJON.E155-E161</ArticleId><ArticleId IdType="pubmed">27857253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cillessen L, Schellekens MPJ, Van de Ven MOM, Donders ART, Compen FR, Bisseling EM, et al. Consolidation and prediction of long-term treatment effect of group and online mindfulness-based cognitive therapy for distressed cancer patients. Acta Oncol. 2018;57(10):1293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0284186X.2018.1479071</ArticleId><ArticleId IdType="pubmed">29932784</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K, Smith A, Diaz A, Shaw J, Butow P, Sharpe L, et al. A systematic review of fear of cancer recurrence among indigenous and minority peoples. Front Psychol. 2021;12: 621850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.621850</ArticleId><ArticleId IdType="pubmed">34012412</ArticleId><ArticleId IdType="pmc">8126623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall DL, Wagner LI, Lebel S, Smith AB, Bergerot CD, Park ER. Guidelines needed for the management of fear of cancer recurrence in adult survivors of cancer in the United States: a consensus statement. Cancer. 2024;130(16):2739&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.35326</ArticleId><ArticleId IdType="pubmed">38630904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>